EI

266.1

-0.6%↓

SHL.DE

49.57

-1.14%↓

ARGX

527

-3.23%↓

FRE

38.7

-2.47%↓

PHIA

22.96

-2.88%↓

EI

266.1

-0.6%↓

SHL.DE

49.57

-1.14%↓

ARGX

527

-3.23%↓

FRE

38.7

-2.47%↓

PHIA

22.96

-2.88%↓

EI

266.1

-0.6%↓

SHL.DE

49.57

-1.14%↓

ARGX

527

-3.23%↓

FRE

38.7

-2.47%↓

PHIA

22.96

-2.88%↓

EI

266.1

-0.6%↓

SHL.DE

49.57

-1.14%↓

ARGX

527

-3.23%↓

FRE

38.7

-2.47%↓

PHIA

22.96

-2.88%↓

EI

266.1

-0.6%↓

SHL.DE

49.57

-1.14%↓

ARGX

527

-3.23%↓

FRE

38.7

-2.47%↓

PHIA

22.96

-2.88%↓

Search

Sanofi SA

Avatud

SektorTervishoid

99.4 -3.7

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

97.94

Max

103.24

Põhinäitajad

By Trading Economics

Sissetulek

-2.3B

499M

Müük

-6.5B

7.6B

P/E

Sektori keskmine

23.216

63.778

Aktsiakasum

1.31

Dividenditootlus

3.79

Kasumimarginaal

6.539

Töötajad

82,878

EBITDA

-3.7B

563M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+13.01% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.79%

2.39%

Järgmine tulemuste avaldamine

24. apr 2025

Turustatistika

By TradingEconomics

Turukapital

-6B

125B

Eelmine avamishind

103.1

Eelmine sulgemishind

99.4

Uudiste sentiment

By Acuity

33%

67%

96 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Sanofi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. märts 2025, 06:43 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

5. veebr 2025, 13:41 UTC

Tulu

Santander Shares Get Boost From Buyback, Better-Than-Expected Results -- 2nd Update

5. veebr 2025, 07:10 UTC

Tulu

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations -- Update

5. veebr 2025, 06:39 UTC

Tulu

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations

26. märts 2025, 06:19 UTC

Market Talk
Tulu

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25. märts 2025, 10:08 UTC

Market Talk

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20. märts 2025, 09:00 UTC

Peamised uudised

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20. märts 2025, 06:05 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20. märts 2025, 06:05 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20. märts 2025, 06:04 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Pay $600M Upfront

20. märts 2025, 06:02 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20. märts 2025, 06:00 UTC

Omandamised, ülevõtmised, äriostud

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18. märts 2025, 09:33 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17. märts 2025, 23:00 UTC

Peamised uudised

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13. märts 2025, 09:50 UTC

Tulu

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13. märts 2025, 09:49 UTC

Tulu

Santander Increased 2024 Cash Payments by 19%

24. veebr 2025, 08:56 UTC

Market Talk
Tulu

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24. veebr 2025, 08:30 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

19. veebr 2025, 06:35 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19. veebr 2025, 06:34 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19. veebr 2025, 06:34 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19. veebr 2025, 06:33 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19. veebr 2025, 06:33 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19. veebr 2025, 06:33 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19. veebr 2025, 06:32 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19. veebr 2025, 06:31 UTC

Omandamised, ülevõtmised, äriostud

Sanofi, CD&R Sign Opella Share Purchase Agreement

14. veebr 2025, 10:55 UTC

Market Talk
Tulu
Omandamised, ülevõtmised, äriostud

NatWest CEO Confident on Organic Growth Prospects -- Market Talk

5. veebr 2025, 07:48 UTC

Market Talk
Tulu

Santander's Results, Guidance, Return Plans All Look Strong -- Market Talk

5. veebr 2025, 06:01 UTC

Tulu

Santander: Franco Joins Getnet From Canadian Fintech Company Nuvei

5. veebr 2025, 06:01 UTC

Tulu

Santander: Getnet's Current CEO, Kush Saxena, Has Decided to Resign

Võrdlus sarnastega

Hinnamuutus

Sanofi SA Prognoos

Hinnasiht

By TipRanks

13.01% tõus

12 kuu keskmine prognoos

Keskmine 115.177 EUR  13.01%

Kõrge 125 EUR

Madal 92 EUR

Põhineb 13 Wall Streeti analüütiku instrumendi Sanofi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

13 ratings

9

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

101.1 / 103.88Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

96 / 386 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.